Boswellic Acid: An Encyclopedic Reference
1. Identity: Botanical and Chemical Overview
Botanical Source and Taxonomy
Boswellic acids (BAs) are pentacyclic triterpenoids belonging to the ursane group, which are the major constituents of the gum resin derived from the plant Boswellia serrata Roxb. of the family Burseraceae. From the gum resin of Boswellia serrata and Boswellia carteri, the pentacyclic triterpene molecules known as boswellic acid (BA) are extracted. The genus Boswellia encompasses multiple commercially important species. The genus Boswellia contains 28 different species of trees and shrubs, including Boswellia frereana (elemi frankincense), Boswellia papyrifera (elephant tree), and Boswellia sacra (frankincense, olibanum).
While other species of boswellia are found throughout the Middle East and Africa, the Boswellia serrata tree grows primarily in India, Bangladesh, Pakistan, and Sri Lanka, preferring climates with flat terrain and dry, rocky ridges and slopes. Boswellia serrata is a branching tree native to the mountainous regions of Northern Africa, India, and the Middle East.
Common Names
Boswellia, also known as Indian Frankincense, Frankincense, Shallaki, or Boswellia serrata, is a tree gum resin extract harvested from Boswellia trees grown in India, North Africa, and the Middle East. The Sanskrit name Shallaki and the Hindi name Salai Guggul are also commonly used.
Chemical Composition of the Gum Resin
B. serrata gum resin is a complex mixture of terpenoids and sugars comprising more than 200 different substances, including polysaccharides, essential oils, proteins, and inorganic compounds. It contains 8–12% essential oils, 45–60% polysaccharides, and 25–35% higher terpenoids.
In the resin, more than 12 different boswellic acids have been identified, but only KBA (11-keto-β-boswellic acid) and AKBA (3-O-acetyl-11-keto-β-boswellic acid) have received significant pharmacological interest. Other identified boswellic acid congeners include α-boswellic acid, β-boswellic acid, 3-O-acetyl-α-boswellic acid, and 3-O-acetyl-β-boswellic acid, among others.
Key Active Compounds
- AKBA (3-O-Acetyl-11-keto-β-boswellic acid): AKBA is the most effective boswellic acid and mostly responsible for B. serrata's anti-inflammatory properties.
- KBA (11-keto-β-boswellic acid): Among the various boswellic acids, 11-keto-β-boswellic acid (KBA) and acetyl-11-keto-β-boswellic acid have been observed to be active.
- β-Boswellic acid: Other BAs, specifically β-boswellic acid, also play an important role, targeting the microsomal prostaglandin E2 synthase-1 (mPGES-1) as well as cathepsin G (CatG), thereby complementing the inflammatory action of KBA and AKBA.
Common Preparations and Dosage Forms
Boswellia is an herbal extract made from the gum resin or bark of the tree and can be taken orally or applied topically. Boswellia is available in health food stores and online in the form of tablets, capsules, extracts, and as an ingredient in topical creams and ointments. In Ayurvedic preparations, the resin has also been formulated in medicated ghee for enhanced uptake.
Standardized commercial extracts include formulations enriched in AKBA content. One proprietary product, selectively enriched with 30% AKBA (BE-30, also known as 5-Loxin®), has been evaluated for its anti-inflammatory potential and underlying molecular mechanism of action. Boswellic acids exhibit well-documented anti-inflammatory and antioxidant activities; however, their therapeutic potential is hindered by their poor aqueous solubility, low intestinal absorption, extensive metabolism, and overall low oral bioavailability. Recent advances in delivery systems, including nanoparticles, micelles, phytosomes, and ligand-targeted carriers, are being explored to improve bioavailability.
2. Traditional and Historical Use
Ayurvedic Medicine (India)
Boswellia, also called Indian Frankincense, is an extract of the gummy oleoresin derived from beneath the bark of the Boswellia serrata tree, which is native to India, the Middle East, and Northern Africa. The resin is rich in triterpenic acids and has been used for centuries in traditional Ayurvedic medicine to treat inflammatory conditions. The gum resin of Boswellia serrata, known in the vernacular as "Sallai guggal," has been used in the Ayurvedic system of medicine for the management of rheumatism, respiratory diseases, and liver disorders.
Boswellia has been used for centuries to treat inflammatory conditions, joint disorders, and respiratory ailments. Ayurvedic formulations often combine frankincense with other botanicals to enhance therapeutic efficacy, particularly in managing rheumatoid arthritis (Amavata) and osteoarthritis. It was primarily prescribed for arthritis (sandhivata), respiratory disorders, diarrhea, and skin diseases.
Ancient Egypt and the Middle East
The Papyrus Ebers—an ancient Egyptian medical text from around 1500 BCE—mentions frankincense as medicine, meaning people were writing about this tree's healing powers over 3,500 years ago. Beyond its medicinal applications, Boswellia resin played integral roles in religious ceremonies; the burning of frankincense in temples and religious gatherings was believed to purify the air and create a connection to the divine.
Broader Cross-Cultural Use
Boswellia has been used in traditional Indian (Ayurveda), Asian, and Middle Eastern wellness systems for thousands of years. Boswellic acids have been in use since ancient times, primarily to treat acute and chronic inflammatory diseases.
3. Key Constituents and Mechanisms of Action
5-Lipoxygenase (5-LOX) Inhibition
Boswellic acids interfere with 5-lipoxygenase (5-LO), the key enzyme in leukotriene biosynthesis, providing a proposed molecular mechanism underlying the anti-inflammatory effectiveness of frankincense preparations. 3-Acetyl-11-keto-β-boswellic acid (AKBA) acts as a natural allosteric inhibitor targeting 5-LOX. AKBA acts directly on the 5-lipoxygenase enzyme at a selective site for pentacyclic triterpenes that is different from the arachidonate substrate binding site.
All six of the primary boswellic acids had inhibition effects against 5-lipoxygenase (5-LOX), with the two most powerful being AKBA and 11-keto-β-BA (KBA). AKBA operates as a non-redox-type, non-competitive inhibitor and binds to 5-LOX in a unique way that is both calcium-dependent and reversible.
The formation of 5-lipoxygenase products from endogenous substrate by intact rat neutrophilic granulocytes and from exogenous arachidonic acid by cell-free preparations was inhibited by AKBA with IC50 values of 1.5 µM, 8 µM, and 16 µM, respectively. With other pentacyclic triterpenes lacking the 11-keto function and/or the carboxyl function on ring A (e.g., amyrin and ursolic acid), no 5-lipoxygenase inhibition was observed. Notably, however, data show that boswellic acids are direct 5-LO inhibitors that efficiently suppress 5-LO product synthesis in common in vitro test models; however, the pharmacological relevance of such interference in vivo seems questionable.
NF-κB Pathway Inhibition
AKBA exhibits anti-TNFα properties in a cellular inflammation model in vitro and inhibitory action on MAPK pathways in inflammation, in addition to anti-NF-κB activities. Boswellic acids possess potent anti-inflammatory properties in vitro by inhibiting 5-lipoxygenase, human leukocyte elastase, and the NF-κB pathway. Cathepsin G was identified as another target of boswellic acids.
Inhibition of Pro-Inflammatory Cytokines
Boswellia extracts as well as boswellic acids including KBA and AKBA have been shown to decrease production of pro-inflammatory cytokines including IL-1, IL-2, IL-6, IFN-γ, and TNF-α.
Complement System Inhibition
Boswellic acids also inhibit the complement system at the level of conversion of C3 into C3a and C3b.
Prostaglandin Synthesis Modulation
The anti-inflammatory actions of BAs are caused by different mechanisms of action. They include inhibition of leukotriene synthesis and, to a lesser extent, prostaglandin synthesis.
Multi-Target Profile
The molecular targets attributed to boswellic acid's wide range of biological activities include transcription factors, kinases, enzymes, receptors, and growth factors. In an extract of the resin of Boswellia species, multiple factors are responsible for the final outcome of a therapeutic effect, be it synergistic or antagonistic. The anti-inflammatory actions of BAs are caused by different mechanisms of action.
4. Pharmacokinetics and Bioavailability
KBA is absorbed, reaching blood levels close to its in vitro IC50; AKBA, which is more active in in vitro studies than KBA, undergoes much less absorption than KBA. However, absorption of both is increased more than twice when taken together with a high-fat meal.
The therapeutic use of boswellic acids is greatly hindered by poor pharmacokinetic properties. Co-administration strategies that facilitate oral absorption and distribution of boswellic acids should lead to safer and more effective use of this product prophylactically and therapeutically in inflammatory disorders.
5. Scientific Evidence by Area of Use
5.1 Osteoarthritis
Osteoarthritis (OA) is the condition for which boswellic acids have the strongest and most consistent clinical evidence base. In a meta-analysis, data from randomized controlled trials were obtained to assess the effects of Boswellia or its extract versus placebo or western medicine in patients with OA, using primary outcomes including visual analogue score (VAS), WOMAC pain, WOMAC stiffness, WOMAC function, and lequesne index. Seven trials involving 545 patients were included. Compared with the control group, Boswellia and its extract may relieve pain (VAS: WMD −8.33; 95% CI −11.19, −5.46; P < 0.00001; WOMAC pain: WMD −14.22; 95% CI −22.34, −6.09; P = 0.0006) and stiffness (WOMAC stiffness: WMD −10.04; 95% CI −15.86, −4.22).
More recent data has further supported these findings. A systematic review and network meta-analysis of 39 randomized controlled trials found that Boswellia significantly improved pain, stiffness, and function in patients with knee osteoarthritis. A randomized, placebo-controlled clinical study (N=80) using a proprietary, standardized Boswellia serrata gum resin extract significantly improved joint pain, musculoskeletal function, and cartilage morphology after 180 days of supplementation in adult volunteers with knee osteoarthritis.
Studies showed that Boswellia serrata extract (such as 5-Loxin and Aflapin) does not have toxic side effects at higher doses. These indicate that the active compound of Boswellia extract (AKBA) is safe based on current evidence.
Evidence strength: Moderate-to-good for short-term symptomatic benefit in OA, based on multiple RCTs and meta-analyses, though trial sizes are generally modest and longer-term data are limited.
5.2 Rheumatoid Arthritis
Clinical studies, so far with pilot character, suggest efficacy in some autoimmune diseases including rheumatoid arthritis. Usage of NSAIDs declined 5.8% in the Boswellia group vs. 3.1% in the placebo group, but no other significant benefit was noted in a study with 78 rheumatoid arthritis outpatients taking 9 tablets (3,600 mg) Boswellia or placebo daily.
Evidence strength: Preliminary and weak. Available clinical data are limited to small pilot-character studies with inconsistent findings.
5.3 Inflammatory Bowel Disease (IBD)
In patients with inflammatory bowel diseases (IBD), including Crohn's disease and chronic colitis, Boswellia extracts significantly improved clinical scores and remission rates, suggesting modulatory effects on intestinal mucosal inflammation.
For ulcerative colitis: Remission of ulcerative colitis was achieved in 14 of 20 patients who received Boswellia gum resin, compared with only 4 of 10 patients who received sulfasalazine—a standard medication for IBD and rheumatoid arthritis. In a clinical study of patients with moderate to severe ulcerative colitis, a Boswellia serrata preparation taken three times daily for six weeks produced remission in 82% of participants. For comparison, the standard pharmaceutical treatment (sulfasalazine) achieved remission in 75% of its group. Blood markers, stool properties, and tissue biopsies all improved. This is a single study and not enough to draw sweeping conclusions, but the results were notable enough to generate continued research interest.
For Crohn's disease: In a randomized controlled trial involving 102 patients with Crohn's disease, those who received Boswellia serrata extract experienced a mean reduction of 90 on the Crohn's Disease Activity Index, compared with 53 for those receiving mesalamine. However, some RCTs have shown no statistically significant differences between treatment and placebo groups in patients with Crohn's disease or collagenous colitis.
Evidence strength: Mixed. Some RCTs show promising results, particularly in ulcerative colitis, but others show no significant benefit, sample sizes are small, and evidence is insufficient to draw definitive conclusions.
5.4 Bronchial Asthma
Bronchial asthma was reduced in 70% of 40 patients treated with gum resin at 300 mg thrice daily for 6 weeks in a double-blind trial (Gupta 1998). In this asthma study, Boswellia extract significantly reduced leukotriene levels in blood, improved FEV1 (forced expiratory volume), and decreased asthma attack frequency compared to placebo over 6 weeks. This aligns with the 5-LOX mechanism, since leukotrienes are major drivers of airway constriction and allergic inflammation in the lungs.
Evidence strength: Preliminary but biologically plausible. Limited to a small number of trials with small sample sizes. Mechanism is well-supported, but clinical evidence requires replication in larger studies.
5.5 Radiation-Induced Cerebral Edema and Brain Tumors
Patients irradiated for brain tumors often suffer from cerebral edema and are usually treated with dexamethasone. To investigate the activity of Boswellia serrata (BS) in radiotherapy-related edema, a prospective, randomized, placebo-controlled, double-blind, pilot trial was conducted. Forty-four patients with primary or secondary malignant cerebral tumors were randomly assigned to radiotherapy plus either BS 4,200 mg/day or placebo, with the volume of cerebral edema in the T2-weighted MRI sequence analyzed as the primary endpoint. Kirste et al. conducted the first randomized placebo-controlled clinical trial to study the efficacy of Boswellia in reducing cerebral edema in brain tumor patients treated with radiation and observed that 60% of patients receiving Boswellia achieved a >75% decrease in edema compared with only 26% in the placebo group. BS significantly reduced cerebral edema measured by MRI in the study population. BS could potentially be steroid-sparing for patients receiving brain irradiation. The findings will need to be further validated in larger studies.
Boswellic acids have also demonstrated neuroprotective potential in central nervous system disorders such as multiple sclerosis (MS), where MRI findings indicated a reduction in cortical lesion progression.
Evidence strength: Preliminary but promising. Largest available RCT in this area involved only 44 patients. Further large-scale validation is needed.
5.6 Respiratory Conditions (Asthma)
In respiratory diseases such as bronchial asthma, Boswellia extracts were associated with improvements in pulmonary function and a reduction in acute exacerbations. This is consistent with the 5-LOX inhibition mechanism, as leukotrienes (particularly LTB4 and LTD4) are well-established mediators of bronchoconstriction. Evidence is limited to small clinical studies.
5.7 General Limitations of the Clinical Evidence Base
There have been several studies on the potential health benefits and safety of using boswellia, but most of these are small and of low quality. Despite substantial progress in preclinical studies, clinical research has not kept pace, particularly in the form of randomized controlled trials (RCTs) utilizing purified BAs such as AKBA and KBA. Most existing clinical studies have employed Boswellia serrata extract as the intervention, which contains a complex mixture of metabolites with undefined BA content. This complexity makes it difficult to attribute therapeutic effects specifically to BAs, thereby limiting the translation of mechanistic findings to human applications. While some RCTs have shown that Boswellia serrata extract may provide clinical benefits for conditions such as rheumatoid arthritis, ulcerative colitis, and asthma, these studies are often limited by small sample sizes, variable control settings, short follow-up periods, and a lack of biomarker validation—rendering the evidence insufficient for firm conclusions.
6. Body Systems and Health Areas Associated with Boswellic Acid
- Musculoskeletal system: Boswellic acids possess promising anti-inflammatory, anti-arthritic, and antirheumatic effects. The greatest weight of clinical evidence relates to osteoarthritis, particularly of the knee.
- Gastrointestinal system: The extract and/or boswellic acids have been found to be effective in ulcerative colitis and other gastrointestinal inflammatory conditions.
- Respiratory system: In respiratory diseases such as bronchial asthma, Boswellia extracts were associated with improvements in pulmonary function and a reduction in acute exacerbations.
- Central nervous system: Boswellic acids have demonstrated neuroprotective potential in CNS disorders, including multiple sclerosis, where MRI findings indicated a reduction in cortical lesion progression. Clinical applications in radiation-induced cerebral edema management are actively being studied.
- Immune system: A major target of BAs is the immune system.
- Oncology (adjunctive): Analogues of boswellic acids are being explored in cancer therapy to address adverse effects of radiotherapy and chemotherapy, where edematous and other inflammatory conditions are being investigated.
7. Dosage Forms and Dosages Reported in Clinical Studies
The following dosages reflect those specifically reported in cited clinical studies and authoritative sources. They are presented for informational purposes as reported in the literature.
- Boswellia is likely to be safe when taken orally. Boswellia serrata extract in doses up to 1,000 mg daily has been safely used in several clinical trials lasting up to 6 months. It has also been used with apparent safety at a dose of 2,400 mg for up to 1 month. (NCCIH)
- Bronchial asthma: 300 mg thrice daily (900 mg/day total) of gum resin for 6 weeks, in a double-blind trial of 40 patients.
- Rheumatoid arthritis: 9 tablets (3,600 mg/day) of Boswellia or placebo daily, in a study of 78 outpatients.
- Cerebral edema / brain tumor irradiation: 4,200 mg/day of Boswellia serrata during radiotherapy, in a double-blind pilot trial of 44 patients.
- For radiation necrosis after radiosurgery: a target dose of 4,050 to 4,500 mg daily was used in a study of 100 patients.
- For knee osteoarthritis: a proprietary standardized extract over 180 days was evaluated in a randomized, placebo-controlled study of 80 adult volunteers.
- In a randomized, double-blind, placebo-controlled trial (N=150), Boswellia serrata extract (BOSMAX®) taken daily for 30–90 days was studied for knee-joint symptoms and inflammatory markers in adults with non/mild osteoarthritis.
The translational gap between robust preclinical efficacy and scant clinical confirmation highlights unresolved issues such as bioavailability, dosage optimization, and a lack of large-scale clinical studies.
8. Safety Considerations and Drug Interactions
General Safety Profile
Animal studies indicate that Boswellia extracts and isolated boswellic acids have relatively low acute toxicity. Reported oral LD50 values in rodents exceed 2,000 mg/kg, suggesting low acute lethality. Extracts of Boswellia serrata have not been linked to serum aminotransferase elevations during treatment or to instances of clinically apparent acute liver injury. (NIH LiverTox)
No serious safety issues were raised in any of the published BS trials reviewed in an early systematic review. Mild and transient effects were reported in 8.7% of patients in one observational cohort study.
Gastrointestinal Adverse Effects
Common side effects include constipation, diarrhea, and an upset stomach.
Drug Interactions: Warfarin and CYP Enzymes
Different species of Boswellia (including Boswellia serrata) could inhibit CYP2C19, CYP3A4, and CYP2C9, the most important isoenzyme metabolizing S-warfarin, possibly increasing warfarin activity. In two cases, INR increase occurred with concomitant intake of warfarin and Boswellia serrata. In both cases, complete recovery was achieved after dechallenge, and the causality relationship was defined as "probable."
Boswellia inhibits several liver enzymes responsible for metabolizing medications, specifically CYP2C9, CYP2C19, and CYP3A4. These enzymes process a wide range of pharmaceutical drugs. The most clinically significant interaction documented so far is with warfarin, a blood thinner. Because Boswellia slows the breakdown of warfarin, it can amplify its anticoagulant effect, raising the risk of bleeding.
Interaction with Immunosuppressants
Boswellia serrata may interact with anticoagulant and antiplatelet medicines (such as warfarin, aspirin), as it could theoretically increase the risk of bleeding. It may also interact with immunosuppressants (like cyclosporine, azathioprine) due to additive immune-modulating effects.
Pregnancy and Breastfeeding
Avoidance of Boswellia during pregnancy is advised, as Boswellia may cause miscarriage. There is no information available about the use of Boswellia while breastfeeding. Safety data for pregnant or breastfeeding women is insufficient.
Bioavailability and Formulation Considerations
Absorption of both KBA and AKBA is increased more than twice when taken together with a high-fat meal. Challenges related to BAs' poor solubility and limited bioavailability are a significant concern for clinical translation.
References
Go back